News Archives | Page 3 of 9 | Aurobindo Pharma USA

Currently Browsing

All News

April 01, 2022


Aurobindo Receives FDA Approval for Acyclovir Oral Suspension USP, 200 mg/5 mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Acyclovir Oral Suspension USP, 200 mg/5 mL. Aurobindo Pharma’s Acyclovir Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), ZOVIRAX ® (acyclovir), of Mylan Pharmaceuticals Inc. Acyclovir Oral Suspension […]

March 29, 2022


Aurobindo Receives FDA Approval for Bromfenac Ophthalmic Solution 0.09%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Bromfenac Ophthalmic Solution 0.09%. Aurobindo Pharma’s Bromfenac Ophthalmic Solution, are an AT-rated generic equivalent to the reference listed drug (RLD), Bromday™ Ophthalmic Solution, of Bausch & Lomb. Bromfenac Ophthalmic Solution are indicated for: Postoperative inflammation and reduction of […]

March 28, 2022


Aurobindo Receives FDA Approval for Clobazam Oral Suspension, 2.5 mg/mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Clobazam Oral Suspension, 2.5mg/mL. Aurobindo Pharma’s Clobazam Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), ONFI® Oral Suspension, of Lundbeck Pharmaceuticals LLC . Clobazam Oral Suspension  are […]

January 12, 2022


Aurobindo Receives FDA Approval for Colchicine Tablets USP, 0.6mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Colchicine Tablets USP, 0.6 mg. Aurobindo Pharma’s Colchicine Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), COLCRYS® Tablets, of Takeda Pharmaceuticals USA, Inc. Colchicine Tablets are indicated in: […]

January 12, 2022


Aurobindo Receives FDA Approval for Nebivolol Tablets, 2.5mg, 5mg, 10mg, and 20mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nebivolol Tablets, 2.5mg, 5mg, 10mg, and 20mg . Aurobindo Pharma’s Nebivolol Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Bystolic® Tablets, of Allergan Sales, LLC. Nebivolol Tablets are […]

November 17, 2021


Aurobindo Receives FDA Approval for Prednisone Tablets USP, 1mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Prednisone Tablets USP, 1mg. Aurobindo Pharma’s Prednisone Tablets USP, 1mg, are an AB-rated generic equivalent to the reference listed drug (RLD), Meticorten® Tablets, of Schering Corp Sub Schering Plough Corp. Prednisone Tablets are […]

September 30, 2021


Aurobindo Receives FDA Approval for Vigabatrin for Oral Solution USP, 500mg

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Vigabatrin for Oral Solution USP, 500 mg . Aurobindo Pharma’s Vigabatrin for Oral Solution USP, 500 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Sabril for Oral Solution of […]

September 23, 2021


Aurobindo Receives FDA Approval for Fenofibrate Capsules, 67mg, 134mg, and 200mg

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Fenofibrate Capsules USP, 67mg, 134mg, and 200mg. Aurobindo Pharma’s Fenofibrate Capsules USP, 67mg, 134mg, and 200mg are an AB-rated generic equivalent to the reference listed drug (RLD), Tricor Capsules of AbbVie, Inc. Fenofibrate […]

August 11, 2021


Aurobindo Receives FDA Approval for Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, and 28mg

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, and 28mg. Aurobindo Pharma’s Memantine Hydrochloride Extended-Release Capsules, 7mg, 14mg, 21mg, and 28mg are an AB-rated generic equivalent to the reference listed drug (RLD), Namenda XR […]

July 21, 2021


Aurobindo Receives FDA Approval for Nifedipine Extended-Release Tablets USP, 30mg, 60mg, and 90mg

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nifedipine Extended-Release Tablets USP, 30 mg, 60mg and 90 mg. Aurobindo Pharma’s Nifedipine Extended-Release Tablets, 30 mg, 60mg, and 90 mg are an AB-rated generic equivalent to the reference listed drug (RLD), ADALAT® CC of Alvogen […]

July 15, 2021


Aurobindo Receives FDA Approval for Baclofen Tablets USP, 10 mg and 20 mg

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Baclofen Tablets USP, 10 mg and 20 mg. Aurobindo Pharma’s Baclofen Tablets USP, 10 mg and 20 mg are an AB-rated generic equivalent to the reference listed drug (RLD), LIORESAL® marketed by Novartis […]

May 17, 2021


Aurobindo Receives FDA Approval for Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, 2%/0.5% (10mL bottles)

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, 2% / 0.5% (10 mL bottles). Aurobindo Pharma’s Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, are an AT-rated generic equivalent to the reference listed drug (RLD), […]